Fig. 7: PIM1/GSK3β signaling is activated in clinical samples of osimertinib-resistant NSCLC. | Cell Death & Disease

Fig. 7: PIM1/GSK3β signaling is activated in clinical samples of osimertinib-resistant NSCLC.

From: PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Fig. 7

A CT images of lung tumor images before and after treatments. The red arrow indicated tumors. NA, not available. B PIM1, p-GSK3β (Ser9) and Vimentin staining in tumor specimens from the same patient before and after treatments. Scale bar, 25 µm. C PIM1, p-GSK3β (Ser9) and Vimentin IHC staining scores of patients before and after osimertinib resistance. Data are presented as mean ± SD, *p < 0.05, **p < 0.01, Student’s t test.

Back to article page